Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours

In this phase I study, the safety, pharmacokinetics, and antitumour activity of the HER2-targeted antibody–drug conjugate A166 were evaluated in patients with HER2-expressing advanced solid tumours. Patients with advanced solid tumours refractory to standard therapies received A166 at doses of 0.1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, Liu, Rujiao, Gao, Shuiping, Li, Wenhua, Chen, Yang, Meng, Yanchun, Liu, Chang, Jin, Wenyue, Wu, Junyan, Wang, Ying, Hao, Yanrong, Yi, Shuli, Qing, Yan, Ge, Junyou, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113253/
https://www.ncbi.nlm.nih.gov/pubmed/37072437
http://dx.doi.org/10.1038/s41523-023-00522-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113253/
https://www.ncbi.nlm.nih.gov/pubmed/37072437
http://dx.doi.org/10.1038/s41523-023-00522-5

Ejemplares similares